Literature DB >> 17401365

Impaired microRNA processing enhances cellular transformation and tumorigenesis.

Madhu S Kumar1, Jun Lu, Kim L Mercer, Todd R Golub, Tyler Jacks.   

Abstract

MicroRNAs (miRNAs) are a new class of small noncoding RNAs that post-transcriptionally regulate the expression of target mRNA transcripts. Many of these target mRNA transcripts are involved in proliferation, differentiation and apoptosis, processes commonly altered during tumorigenesis. Recent work has shown a global decrease of mature miRNA expression in human cancers. However, it is unclear whether this global repression of miRNAs reflects the undifferentiated state of tumors or causally contributes to the transformed phenotype. Here we show that global repression of miRNA maturation promotes cellular transformation and tumorigenesis. Cancer cells expressing short hairpin RNAs (shRNAs) targeting three different components of the miRNA processing machinery showed a substantial decrease in steady-state miRNA levels and a more pronounced transformed phenotype. In animals, miRNA processing-impaired cells formed tumors with accelerated kinetics. These tumors were more invasive than control tumors, suggesting that global miRNA loss enhances tumorigenesis. Furthermore, conditional deletion of Dicer1 enhanced tumor development in a K-Ras-induced mouse model of lung cancer. Overall, these studies indicate that abrogation of global miRNA processing promotes tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401365     DOI: 10.1038/ng2003

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  655 in total

1.  Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.

Authors:  Moubin Lin; Jian Gu; Cathy Eng; Lee M Ellis; Michelle A Hildebrandt; Jie Lin; Maosheng Huang; George A Calin; Dingzhi Wang; Raymond N Dubois; Ernest T Hawk; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2012-06-01       Impact factor: 12.531

Review 2.  From microRNAs to targets: pathway discovery in cell fate transitions.

Authors:  Deepa Subramanyam; Robert Blelloch
Journal:  Curr Opin Genet Dev       Date:  2011-06-01       Impact factor: 5.578

3.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Micro-RNAs and breast cancer.

Authors:  John Le Quesne; Carlos Caldas
Journal:  Mol Oncol       Date:  2010-04-28       Impact factor: 6.603

Review 5.  Non-coding RNAs in cancer initiation and progression and as novel biomarkers.

Authors:  S Patrick Nana-Sinkam; Carlo M Croce
Journal:  Mol Oncol       Date:  2011-10-31       Impact factor: 6.603

6.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Authors:  Youl-Nam Lee; Stephanie Brandal; Pierre Noel; Erik Wentzel; Joshua T Mendell; Michael A McDevitt; Reuben Kapur; Melody Carter; Dean D Metcalfe; Clifford M Takemoto
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

Review 7.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 8.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

9.  Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.

Authors:  Hung-Lung Ke; Meng Chen; Yuanqing Ye; Michelle A T Hildebrandt; Wen-Jeng Wu; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

10.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Authors:  Christian J Braun; Xin Zhang; Irina Savelyeva; Sonja Wolff; Ute M Moll; Troels Schepeler; Torben F Ørntoft; Claus L Andersen; Matthias Dobbelstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.